Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en niños y adolescentes.

V. resumida | Consulta rápida | Info. pacientes

  1. Introducción
  2. Alcance y objetivos
  3. Metodología
  4. El TDAH
  5. Diagnóstico
  6. Instrumentos de evaluación
  7. Tratamiento
  8. Prevención
  9. Aspectos éticos y legales
  10. Estrategias diagnósticas y terapeúticas
  11. Difusión e implementación
  12. Recomendaciones de investigación futura
  13. Bibliografía

<
Abre nueva ventana: Bibliografía en versión pdf
Descargar GPC sobre TDAH (1,87 Mb)

Bibliografía

1. Scottish Intercollegiate Guidelines Network (SIGN). Attention defi cit and hyperkinetic disorders in children and young people. 2005.

2. National Institute for Health and Clinical Excellence. Attention defi cit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Great Britain: The British Psychological Society and The Royal College of Psychiatrist; 2009.

3. Still GF. Some abnormal psychical condiction in chidren. Lancet. 1902;i:1008-12.

4. Tredgold AF. Mental defi ciency (Amentia). New York: Wood; 1908.

5. Bradley W. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;94:577-85.

6. Barkley RA. The Nature of ADHD. History. En: Barkley RA, editor. Attention-Defi cit Hyperactivity Disorder. A Handbook for diagnosis and treatment. 3.ª ed. London: The Guilford Press; 2006. pp. 3-75.

7. Lauferr MW, Denhoff E. Hyperkinetic behavior syndrome in children. J Pediatr. 1957 Apr;50(4):463-74.

8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2.ª ed. Washington: 1968.

9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3.ª ed. Washington: 1980.

10. American Psychiatric Association. DSM-IV TR Manual diagnóstico y estadístico de los trastornos mentales-IV Texto revisado. Barcelona: Masson; 2001.

11. Benjumea P. Trastornos hipercinéticos. Guía para su diagnóstico. En: Ballesteros C, editor. Práctica clínica paidopsiquiátrica. Historia Clínica. Guías Clínicas. Madrid: Adalia; 2006. pp. 116-28

12. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/ hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry. 2001 May;40(5):508-15.

13. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164164(6): 942-8.

14. Cardo E, Servera M, Llobera J. Estimation of the prevalence of attention defi cit hyperactivity disorder among the standard population on the island of Majorca. Rev Neurol. 2007 Jan 1;44(1):10-4.

15. Andrés MA, Català MA, Gómez-Beneyto M. Prevalence, comorbidity, risk factors and service utilisation of disruptive behaviour disorders in a community sample of children in Valencia (Spain). Soc Psychiatry Psychiatr Epidemiol. 1999;34(175):179.

16. Gómez-Beneyto M, Bonet A, Català M, Puche E, Vila V. Prevalence of Mental Disorders Among Children in Valencia, Spain. Acta Psychiatr Scand. 1994;89:352-7.

17. Benjumea P, Mojarro MA. Trastornos hipercinéticos: estudio epidemiológico en doble fase ón sevillana. Anales de Psiquiatría. 1993 Jul;9(7):306-11.

18. Farré-Riba A, Narbona J. Índice de hipercinesia y rendimiento escolar. Validación del cuestionario de Conners en nuestro medio. Acta Pediatr Esp. 1989;47:103-9.

19. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, et al. ADHD comorbidity fi ndings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):147-58.

20. Szatmari P, Offord DR, Boyle MH. Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry. 1989 Mar;30(2):219-30.

21. Criado Álvarez JJ, Romo BC. Variability and tendencies in the consumption of methylphenidate in Spain. An estimation of the prevalence of attention defi cit hyperactivity disorder. Rev Neurol 2003 Nov 1;37(9):806-10.

22. Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard CB, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol. 2008 Mar;64(3):311-7.

23. Bonati M, Clavenna A. The epidemiology of psychotropic drug use in children and adolescents. Int Rev Psychiatry. 2005 Jun;17(3):181-8.

24. Beitchman JH, Wekerle C, Hood J. Diagnostic continuity from preschool to middle childhood. J Am Acad Child Adolesc Psychiatry. 1987 Sep;26(5):694-9.

25. Johnston C, Mash EJ. Families of children with attention-defi cit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev. 2001 Sep;4(3): 183-207.

26. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-defi cit/ hyperactivity disorder in children and adolescents. Council on Scientifi c Affairs, American Medical Association. JAMA. 1998 Apr 8;279(14):1100-7.

27. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, et al. Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry. 1999 Jul;38(7):797-804.

28. Dopfner M, Rothenberger A, Sonuga-Barke E. Areas for future investment in the field of ADHD: preschoolers and clinical networks. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1: I130-I135.

29. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 1995;7(3):373-8.

30. Barkley RA. Symptoms, diagnosis, prevalence and gender differences 26. En: Barkley RA, editor. Attention-Defi cit Hyperactivity Disorder. A Handbook for diagnosis and treatment. ªed. London: The Gilford Press; 2006. pp. 77-121.

31. Cardo E, Servera M. Attention defi cit hyperactivity disorder: the state of the matter and further research approaches. Rev Neurol. 2008 Mar 16;46(6):365-72.

32. Barkley RA, Cox D. A review of driving risks and impairments associated with attentiondefi cit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res. 2007;38(1):113-28.

33. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993 Jul;50(7):565-76.

34. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 1998 Apr;155(4):493-8.

35. Mannuzza S, Klein RG, Bessler A, Malloy P, Hynes ME. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1222-7.

36. Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, Addalli KA. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry. 1991 Jan;48(1): 77-83.

37. Mannuzza S, Klein RG, Addalli KA. Young adult mental status of hyperactive boys and their brothers: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1991 Sep;30(5): 743-51.

38. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry. 1997 Aug;36(8):1065-79.

39. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-defi cit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999 Dec;56(12):1073-86.

40. Wilens TE, Prince JB, Biederman J, Spencer TJ, Frances RJ. Attention-defi cit hyperactivity disorder and comorbid substance use disorders in adults. Psychiatr Serv. 1995; 46(8): 761-765.

41. Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis S, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):21-9.

42. Faraone SV, Biederman J, Mennin D, Russell R, Tsuang MT. Familial subtypes of attention defi cit hyperactivity disorder: a 4-year follow-up study of children from antisocial-ADHD families. J Child Psychol Psychiatry. 1998 Oct;39(7):1045-53.

43. Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-defi cit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005 Sep;116(3):e364-e369.

44. Mash EJ, Johnston C. Parental perceptions of child behavior problems, parenting self-esteem, and mothers’ reported stress in younger and older hyperactive and normal children. J Consult Clin Psychol. 1983 Feb;51(1):86-99.

45. Schlander M. Impact of Attention-Defi cit/Hyperactivity Disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence. Child Adolesc Psychiatry Ment Health. 2007;1(1):13.

46. Grupo de trabajo sobre guías de práctica clínica. Elaboración de guías de práctica clínica en el Sistema Nacional de Salud. Manual metodológico. Guías de Práctica Clínica en el Sistema Nacional de Salud: I+CS Nº 2006/1. ed. Madrid: Instituto Aragonés de Ciencias de la Salud- I+CS; 2007.

47. Grupo de trabajo sobre actualización de GPC. Actualización de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC; 2008.

48. Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, et al. DSM-IV fi eld trials for attention defi cit hyperactivity disorder in children and adolescents. Am J Psychiatry. 1994 Nov;151(11):1673-85.

49. Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, et al. Infl uence of gender on attention defi cit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry. 2002 Jan;159(1):36-42.

50.Quinn P, Wigal S. Perceptions of girls and ADHD: results from a national survey. MedGen- Med. 2004;6(2):2.

51. Spencer TJ. ADHD and Comorbidity in Childhood. J Clin Psychiatry. 2007;67(Suppl 8):27- 31.

52. Seidman LJ. Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev. 2006 Aug;26(4):466-85.

53. Shaywitz BA, Klopper JH, Gordon JW. Methylphenidate in 6-hydroxydopamine-treated developing rat pups. Effects on activity and maze performance. Arch Neurol. 1978 Jul;35(7): 463-9.

54. Arnsten AF. Fundamentals of attention-defi cit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry. 2006;67 Suppl 8:7-12.

55. Shaw P, Eckstrand K, Sharp W. Attention-defi cit/hyperactivity disorder is characterized by a delay in cortical maduration. Proc Natl Acad Sci. 2007;104(49):19649-54.

56. Castellanos FX, Tannock R. Neuroscience of attention-defi cit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002 Aug;3(8):617-28.

57. Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-defi cit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1263-72.

58. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-defi cit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry. 2005 Jun 1;57(11):1273-84.

59. Pliszka SR, Glahn DC, Semrud-Clikeman M, Franklin C, Perez R, III, Xiong J, et al. Neuroimaging of inhibitory control areas in children with attention defi cit hyperactivity disorder who were treatment naive or in long-term treatment. Am J Psychiatry. 2006 Jun;163(6):1052-60.

60. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-defi cit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1313- 23.

61. Smalley SL, Kustanovich V, Minassian SL, Stone JL, Ogdie MN, McGough JJ, et al. Genetic linkage of attention-defi cit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. Am J Hum Genet. 2002 Oct;71(4):959-63.

62. Ribases M, Hervás A, Ramos-Quiroga JA, Bosch R, Bielsa A, Gastaminza X, et al. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-defi cit/hyperactivity disorder. Biol Psychiatry. 2008 May 15;63(10):935-45.

63. Botting N, Powls A, Cooke RW, Marlow N. Attention defi cit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years. J Child Psychol Psychiatry. 1997 Nov;38(8):931-41.

64. Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, Rodriguez A, et al. Maternal lifestyle factors in pregnancy risk of attention defi cit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry. 2003 Jun;160(6):1028-40.

65. Ornoy A, Segal J, Bar-Hamburger R, Greenbaum C. Developmental outcome of school-age children born to mothers with heroin dependency: importance of environmental factors. Dev Med Child Neurol. 2001 Oct;43(10):668-75.

66. Tuthill RW. Hair lead levels related to children’s classroom attention-defi cit behavior. Arch Environ Health. 1996 May;51(3):214-20.

67. Millichap JG. Etiologic classifi cation of attention-defi cit/hyperactivity disorder. Pediatrics. 2008 Feb;121(2):e358-e365.

68. Biederman J, Faraone SV, Monuteaux MC. Differential effect of environmental adversity by gender: Rutter’s index of adversity in a group of boys and girls with and without ADHD. Am J Psychiatry. 2002 Sep;159(9):1556-62.

69. Lehn H, Derks EM, Hudziak JJ, Heutink P, van Beijsterveldt TC, Boomsma DI. Attention problems and attention-defi cit/hyperactivity disorder in discordant and concordant monozygotic twins: evidence of environmental mediators. J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):83-91.

70. Thapar A, Harold G, Rice F, Langley K, O’Donovan M. The contribution of gene-environment interaction to psychopathology. Dev Psychopathol. 2007;19(4):989-1004.

71. McArdle P. Attention-defi cit hyperactivity disorder and life-span development. Br J Psychiatry. 2004 Jun;184:468-9.

72. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921.

73. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-defi cit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005 Jun 1;57(11):1336-46.

74. Pennington BF. Toward a new neuropsychological model of attention-defi cit/hyperactivity disorder: subtypes and multiple defi cits. Biol Psychiatry. 2005 Jun 1;57(11):1221-3.

75. Barkley R. ADHD and the nature of self-control. New York: 1997.

76. Nigg JT, Willcut E, Doyle A, Sonuga-Barke E. Causal heterogeneity in attention-defi cit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry. 2005 Jun;57(11):1224-30.

77. Sonuga-Barke EJ. Causal models of attention-defi cit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry. 2005 Jun;57(11):1231-8.

78. Sergeant JA. Modeling attention-defi cit/hyperactivity disorder: a critical appraisal of the cognitive- energetic model. Biol Psychiatry. 2005 Jun;57(11):1248-55.

79. Soutullo C, Diez A. Manual de Diagnóstico y Tratamiento del TDAH. Ed. Médica Panamericana. Madrid: 2007.

80. Doyle AE. Executive functions in attention-defi cit/hyperactivity disorder. J Clin Psychiatry. 2006;67 Suppl 8:21-6.

81. Gjone H, Stevenson J, Sundet JM. Genetic infl uence on parent-reported attention-related problems in a Norwegian general population twin sample. J Am Acad Child Adolesc Psychiatry. 1996 May;35(5):588-96.

82. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. Developmental change in attentiondefi cit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol. 1995 Dec;23(6):729-49.

83. Hechtman L. Attention-Defi cit Hyperactivity-Disorder. En: American Psychiatric Press, editor. Do They Grow out of it? Long-term outcomes of childhood disorders. Washington, DC: Hechtman L. ed. 1996; pp. 17-38.

84.Levy F, Hay D, Rooney R. Predictors of persistence of ADHD symptoms in a large-scale twin study: preliminary report. 1996. Report No.: 4.

85. Moffitt TE. Juvenile delinquency and attention defi cit disorder: boys’ developmental trajectories from age 3 to age 15. Child Dev. 1990 Jun;61(3):893-910.

86. Taylor E, Chadwick O, Heptinstall E, Danckaerts M. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry. 1996 Sep;35(9): 1213-26.

87. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-defi cit/hyperactivity disorder into young adulthood as a function of reporting source and defi nition of disorder. J Abnorm Psychol. 2002 May;111(2):279-89.

88. Lambert NM. Adolescent outcomes for hyperactive children. Perspectives on general and specifi c patterns of childhood risk for adolescent educational, social, and mental health problems. Am Psychol. 1988 Oct;43(10):786-99.

89. Lie N. Follow-ups of children with attention defi cit hyperactivity disorder (ADHD). Review of literature. Acta Psychiatr Scand Suppl. 1992;368:1-40.

90. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention defi - cit hyperactivity disorder. Am J Psychiatry. 1993 Dec;150(12):1792-8.

91. Klein RG, Mannuzza S. Long-term outcome of hyperactive children: a review. J Am Acad Child Adolesc Psychiatry. 1991 May;30(3):383-7.

92. Biederman J, Faraone SV, Milberger S, Jetton JG, Chen L, Mick E, et al. Is childhood oppositional defi ant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry. 1996 Sep;35(9): 1193-204.

93. Biederman J, Faraone SV, Taylor A, Sienna M, Williamson S, Fine C. Diagnostic continuity between child and adolescent ADHD: fi ndings from a longitudinal clinical sample. J Am Acad Child Adolesc Psychiatry. 1998 Mar;37(3):305-13.

94. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry. 1985 Mar;24(2):211-20.

95. Mannuzza S, Klein R. Long Term Prognosis in Attention Defi cit Hyperactivity Disorder. Child Adolesc Psychiatr Clin N Am. 2000 Jun;9(3):711-20.

96. Loney JKM. The hyperactive child grows up: Predictors of symptoms, delinquency and achievement at follow. En: Gadow K & Loney J, editores. Psychosocial aspects of drug treatment for hyperactivity. Boulder, CO: Westview Press.; 1982; pp. 351-415.

97. Weiss G, Hechtman L. Hyperactive Children Grown Up. 2.ª ed. New York: Guilford Press; 1993.

98. Lynskey MT, Fergusson DM. Childhood conduct problems, attention defi cit behaviors, and adolescent alcohol, tobacco, and illicit drug use. J Abnorm Child Psychol. 1995 Jun;23(3):281- 302.

99. Babinski LM, Hartsough CS, Lambert NM. Childhood conduct problems, hyperactivity-impulsivity, and inattention as predictors of adult criminal activity. J Child Psychol Psychiatry. 1999 Mar;40(3):347-55.

100. Merrell C, Tymms PB. Inattention, hyperactivity and impulsiveness: their impact on academic achievement and progress. Br J Educ Psychol. 2001 Mar;71(Pt 1):43-56.

101. Biederman J, Mick E, Faraone SV, Burback M. Patterns of remission and symptom decline in conduct disorder: a four-year prospective study of an ADHD sample. J Am Acad Child Adolesc Psychiatry. 2001 Mar;40(3):290-8.

102. August GJ, Stewart MA, Holmes CS. A four-year follow-up of hyperactive boys with and without conduct disorder. Br J Psychiatry. 1983 Aug;143:192-8.

103. Fergusson DM, Lynskey MT, Horwood LJ. Factors associated with continuity and changes in disruptive behavior patterns between childhood and adolescence. J Abnorm Child Psychol. 1996 Oct;24(5):533-53.

104. Fischer M, Barkley RA, Fletcher KE, Smallish L. The adolescent outcome of hyperactive children: predictors of psychiatric, academic, social, and emotional adjustment. J Am Acad Child Adolesc Psychiatry. 1993 Mar;32(2):324-32.

105. Lambert NM, Hartsough CS, Sassone D, Sandoval J. Persistence of hyperactivity symptoms from childhood to adolescence and associated outcomes. Am J Orthopsychiatry. 1987 Jan;57(1):22-32.

106. Paternite C, Loney J. Childhood hyperkinesis: Relationships between symptomatology and home environment. En: Whalen CK, Henker B, editores. Hyperactive children: The social ecology of identifi cation and treatment. New York: Academic Press; 1980.

107. Mannuzza S, Klein RG, Moulton JL, III. Lifetime criminality among boys with attention defi cit hyperactivity disorder: a prospective follow-up study into adulthood using offi cial arrest records. Psychiatry Res. 2008 Sep 30;160(3):237-46.

108. Satterfi eld JH, Schell A. A prospective study of hyperactive boys with conduct problems and normal boys: adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1726-35.

109. Pliszka SR, Carlson CL, Swanson JM. ADHD with Comorbid Disorders: Clinical Assessment and Management. New York: Guilford; 1999.

110. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry. 2001 May;42(4):487-92.

111. Organización Mundial de la Salud. Clasifi cación Estadística Internacional de Enfermedades écima Revisión CIE-10. 1992.

112. Subcommitee on Attention-Defi cit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: diagnosis and evaluation of the child with attentiondefi cit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics. 2000 May;105(5): 1158-70.

113. Biederman J, Gao H, Rogers AK, Spencer TJ. Comparison of parent and teacher reports of attention-defi cit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry. 2006 Nov 15;60(10):1106-10.

114. Jakobson A, Kikas E. Cognitive functioning in children with and without Attention-defi cit/ Hyperactivity Disorder with and without comorbid learning disabilities. J Learn Disabil. 2007 May;40(3):194-202.

115. Geurts HM, Verté S, Oosterlaan J, Roeyers H, Sergeant JA. ADHD subtypes: do they differ in their executive functioning profi le? Arch Clin Neuropsychol. 2005 Jun;20(4):457-77.

116. Culpepper L. Primary care treatment of attention-defi cit/hyperactivity disorder. J Clin Psychiatry. 2006;67 Suppl 8:51-8.

117. Diagnosis of Attention-Defi cit/Hyperactivity Disorder. Summary, Technical Review: Number 3, August 1999. Agency for Health Care Policy and Research 2009. Disponible en: URL: http: //www.ahrq.gov/clinic/epcsums/adhdsutr.htm

118. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R, McGoey KE, Ikeda MJ. Teacher ratings of attention defi cit hyperactivity disorder symptoms: Factor structure and normative data. Psychol Assess. 1997 Dec;9(4):436-44.

119. DuPaul GJ, Anastopoulos AD, Power TJ, Reid R, Ikeda MJ, McGoey KE. Parent ratings of attention-defi cit/hyperactivity disorder symptoms: Factor structure and normative data. J Psychopathol Behav Assess. 1998 Mar;20(1):83-102.

120. Servera M, Cardo E. ADHD Rating Scale-IV in a sample of Spanish schoolchildren: normative data and internal consistency for teachers and parents. Rev Neurol. 2007 Oct 1;45(7): 393-9.

121. Farre-Riba A, Narbona J. Conners’ rating scales in the assessment of attention defi cit disorder with hyperactivity (ADHD). A new validation and factor analysis in Spanish children. Rev Neurol. 1997 Feb;25(138):200-4.

122. Multi-Health Systems Inc. 2009. Disponible en: URL: http://www.mhs.com/conners/

123. Conners CK, Sitarenios G, Parker JD, Epstein JN. Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998 Aug;26(4):279-91.

124. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998 Aug;26(4):257-68.

125. Amador Campos JA, Santacana MF, Olmos JG, Cebollero M. Utilidad diagnóstica del Cuestionario TDAH y del Perfi l de atención para discriminar entre niños con Trastorno por défi cit de atención con hiperactividad, Trastornos del aprendizaje y controles. Anuario de Psicología. 2005 Sep;36(2):211-24.

126. Amador Campos JA, Santacana MF, Olmos J, Cebollero M. Estructura factorial y datos descriptivos del perfi l de atención y del cuestionario TDAH para niños en edad escolar. Psicothema. 2006 Nov;18(4):696-703.

127. Manuel García Pérez, Ángela Magaz Lago. EMTDA-H. Escalas Magallanes de Evaluación del Trastorno por Défi cit de Atención con Hiperactividad. España: Grupo Albor-Cohs; 2000.

128. Swanson JM. SNAP-IV Teacher and Parent Ratings Scale. En: Fine AyKR, editor. Therapist’s guide to learning and attention disorders. Nueva York: Academic Press; 2003. pp. 487-500.

129. Achenbach TM. Manual for the Child Behavior Checklist/5-18 and 1991 profi le. University of Vermont DoP, editor. 1991. Burlington, VT.

130. UAB. Unidad de Epidemiología y diagnóstico en psicopatología del desarrollo. 2001.

131. Reynolds C, Kamphaus RW. Behavior Assessment System for Children. Manual. Circle Pine, Mn: American Guidance Service; 1992.

132. González J, Fernández S, Pérez E, Santamaría P. BASC Sistema de evaluación de la conducta de niños y adolescentes. Madrid: TEA Ediciones, S.A.; 2004.

133. Goodman R. The Strengths and Diffi culties Questionnaire: a research note. J Child Psychol Psychiatry. 1997 Jul;38(5):581-6.

134. García Cortizar P, Mazaira JA, Goodman R. Validación inicial de la versión gallega del Cuestionario de Capacidades y Difi cultades (SDQ). Revista de Psiquiatría Infanto-Juvenil 2000;2: 95-100.

135. Herjanic B, Reich W. Development of a structured psychiatric interview for children: agreement between child and parent on individual symptoms. J Abnorm Child Psychol. 1982 Sep;10(3):307-24.

136. de la Osa N, Ezpeleta L, Domenech J, Blas J, Losilla J. Fiabilidad entre entrevistadores de la DICA-R. Psicothema. 1996;8(2):359-68.

137. Ezpeleta L, de la Osa N, Domenech JM, Navarro JB, Losilla JM, Judez J. Diagnostic agreement between clinicians and the Diagnostic Interview for Children and Adolescents--DICAR-- in an outpatient sample. J Child Psychol Psychiatry. 1997 May;38(4):431-40.

138. Chambers WJ, Puig-Antich J, Hirsch M, Paez P, Ambrosini PJ, Tabrizi MA, et al. The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch Gen Psychiatry. 1985 Jul;42(7):696-702.

139. Ulloa RE, Ortiz S, Higuera F, Nogales I, Fresan A, Apiquian R, et al. Interrater reliability of the Spanish version of Schedule for Affective Disorders and Schizophrenia for School-Age Children-- Present and Lifetime version (K-SADS-PL). Actas Esp Psiquiatr. 2006 Jan;34(1):36-40.

140. de la Peña F, Ulloa R, Higuera F, Ortiz S, Arechavaleta B, Foullux C, et al. Interrater reliability of the Spanish version of the KSADS-PL. Scientifi c Proceedings page 95. 2002. San Francisco, CA. American Academy of Child & Adolescent Psychiatry Annual Meeting. New Research Poster A35.

141. Shaffer D, Fisher PW, Lucas CP. Respondent-based interviews. En: Shaffer D, Lucas CP, Richters JE, editores. Diagnostic assessment in child and adolescent psychopathology. New York: Guilford; 1999. pp. 3-33.

142. Bravo M, Ribera J, Rubio-Stipec M, Canino G, Shrout P, Ramirez R, et al. Test-retest reliability of the Spanish version of the Diagnostic Interview Schedule for Children (DISC-IV). J Abnorm Child Psychol. 2001 Oct;29(5):433-44.

143. Sanders MR, Mazzucchelli,TG, Studman L. Stepping Stones Triple P - An evidence-based positive parenting program for families with a child who has a disability: its theoretical basis and development. J Intellect Dev Disabil. 2004;29:1-19.

144. Webster-Stratton C, Reid MJ, Hammond M. Treating children with early-onset conduct problems: intervention outcomes for parent, child, and teacher training. J Clin Child Adolesc Psychol. 2004 Mar;33(1):105-24.

145. Cunningham CE, Bremner R, Secord M. Community Parent Education Program: A schoolbased family systems oriented course for parents of children with disruptive behavior disorders. Ontario, Canadá, Hamilton Heath Sciences Corp. 1998.

146. Bjornstad G, Montgomery P. Terapia familiar para el trastorno por défi cit de atención e hiperactividad en niños y adolescentes. (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.updatesoftware. com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).

147. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PL. Effi cacy of Methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a metaanalysis. Clin Psychol Rev. 2008 Jul;28(5):783-800.

148. Pfiffner LJ, Yee MA, Huang-Pollock C, Easterlin B, Zalecki C, McBurnett K. A randomized, controlled trial of integrated home-school behavioral treatment for ADHD, predominantly inattentive type. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1041-50.

149. Bor W, Sanders MR, Markie-Dadds C. The effects of the Triple P-Positive Parenting Program on preschool children with co-occurring disruptive behavior and attentional/hyperactive diffi culties. J Abnorm Child Psychol. 2002 Dec;30(6):571-87.

150. Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-defi cit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry. 2001 Apr;40(4):402-8.

151. Hoath FE, Sanders MR. A feasibility study of enhanced group triple P - Positive Parenting Program for parents of children with Attention-Defi cit/Hyperactivity Disorder. Behaviour Change. 2002;19:191-206.

152. van den Hoofdakker BJ, van der Veen-Mulders L, Sytema S, Emmelkamp PM, Minderaa RB, Nauta MH. Effectiveness of behavioral parent training for children with ADHD in routine clinical practice: a randomized controlled study. J Am Acad Child Adolesc Psychiatry 2007 Oct;46(10):1263-71.

153. Bloomquist ML, August GJ, Ostrander R. Effects of a school-based cognitive-behavioral intervention for ADHD children. J Abnorm Child Psychol. 1991 Oct;19(5):591-605.

154. Fehlings DL, Roberts W, Humphries T, Dawe G. Attention defi cit hyperactivity disorder: does cognitive behavioral therapy improve home behavior? J Dev Behav Pediatr. 1991 Aug;12(4): 223-8.

155. Pfiffner LJ, McBurnett K. Social skills training with parent generalization: treatment effects for children with attention defi cit disorder. J Consult Clin Psychol. 1997 Oct;65(5):749-57.

156. Tutty S, Gephart H, Wurzbacher K. Enhancing behavioral and social skill functioning in children newly diagnosed with attention-defi cit hyperactivity disorder in a pediatric setting. J Dev Behav Pediatr. 2003 Feb;24(1):51-7.

157. Antshel KM, Remer R. Social skills training in children with attention defi cit hyperactivity disorder: a randomized-controlled clinical trial. J Clin Child Adolesc Psychol. 2003 Mar;32(1): 153-65.

158. González LO, Sellers EW. The effects of a stress-management program on self-concept, locus of control, and the acquisition of coping skills in school-age children diagnosed with attention defi cit hyperactivity disorder. J Child Adolesc Psychiatr Nurs. 2002 Jan;15(1):5-15.

159. Horn WF, Ialongo NS, Pascoe JM, Greenberg G, Packard T, Lopez M, et al. Additive effects of psychostimulants, parent training, and self-control therapy with ADHD children. J Am Acad Child Adolesc Psychiatry. 1991;30(2):233-40.

160. Anastopoulos AD, Shelton TL, DuPaul GJ, Guevremont DC. Parent training for attentiondeficit hyperactivity disorder: its impact on parent functioning. J Abnorm Child Psychol. 1993 Oct;21(5):581-96.

161. Brown RT, Wynne ME, Medenis R. Methylphenidate and cognitive therapy: A comparison of treatment approaches with hyperactive boys. J Abnorm Child Psychol. 1985 Mar;13(1):69-87.

162. Brown RT, Borden KA, Wynne ME, Schleser R, Clingerman SR. Methylphenidate and cognitive therapy with ADD children: a methodological reconsideration. J Abnorm Child Psychol. 1986 Dec;14(4):481-97.

163. Horn WF, Ialongo N, Greenberg G, Packard T, Smith-Winberry C. Additive effect of behavioral parent training and self-control therapy with attention defi cit hyperactivity disordered children. J Clin Child Psychol. 1990;19:98-110.

164. Klein RG, Abikoff H. Behavior therapy and methylphenidate in the treatment of children with ADHD. J Atten Disord 1997 Jul;2(2):89-114.

165. Miranda A, Presentación MJ. Effi cacy of cognitive-behavioral therapy in the treatment of children with ADHD, with and without aggressiveness. Psychol Sch. 2000;27:169-82.

166. Miranda A, Presentación MJ, Soriano M. Effectiveness of a school-based multicomponent program for the treatment of children with ADHD. J Learn Disabil. 2002 Nov;35(6):546-62.

167. Horn WF, Ialongo N, Popvich S, Peradotto D. Behavioral parent training and cognitive behavioral self-control therapy with ADD-H children: Comparative and combined effects. J Clin Child Psychol. 1987;16:57-68.

168. National Institute for Health and Clinical Excellence. Parent-training/education programmes in the management of children with conduct disorders. London, UK; 2006.

169. Barlow J, Stewart-Brown S. Behavior problems and group-based parent education programs. J Dev Behav Pediatr. 2000 Oct;21(5):356-70.

170. Richardson J, Joughin C. Parent-Training Programmes for the Management of Young children with Conduct Disorders. London: Gaskell; 2002.

171. Serketich W, Dumas JE. The effectiveness of behavioural parent-training to modify antisocial behaviour in children: a meta-analysis. Behav Ther. 1996;27:171-86.

172. Dimond C, Hyde C. Parent education programmes for children’s behaviour problems, medium to long term effectiveness. Birmingham: West Midlands Development and Evaluation Service; 1999.

173. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-defi cit/ hyperactivity disorder. Pediatrics. 2004 Apr;113(4):754-61.

174. Castorina J, Aisemberg B, Dibar Ure C, Palau G, Colinvaux C. Obstáculos epistemológicos en la constitución de la disciplina psicopedagógica. En: Miño y Dávila, editor. Problemas en psicología genética. Buenos Aires: 1989.

175. Wells KC, Pelham WE, Kotkin RA, Hoza B, Abikoff HB, Abramowitz A, et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol. 2000 Dec;28(6):483-505.

176. Langberg JM, Epstein JN, Urbanowicz CM, Simon JO, Graham AJ. Effi cacy of an organization skills intervention to improve the academic functioning of students with attentiondefi cit/hyperactivity disorder. Sch Psychol Q. 2008 Sep;23(3):407-17.

177. DuPaul GJ, Eckert TL. The effects of school-based interventions for Attention Defi cit Hyperactivity Disorder: A meta-analysis. School Psych Rev. 1997;26(1):5-27.

178. Mena B, Nicolau R, Salat L, Tort P, Romero B. El alumno con TDAH. Guía práctica para educadores. Mayo ediciones. Barcelona: 2007.

179. Institute for Clinical Systems Improvement. Diagnosis and management of attention defi cit hyperactivity disorder in primary care for school age children and adolescents. Bloomington, MN: ICSI, 2007.

180. Subcommittee on Attention-Defi cit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical Practice Guideline: Treatment of the School-Aged Child With Attention- Defi cit/Hyperactivity Disorder. Pediatrics. 2001 Oct;108(4):1033-44.

181. Kapalka GM. Avoiding repetitions reduces ADHD children’s management problems in the classroom. Emotional & Behavioural Diffi culties. 2005 Dec;10(4):269-79.

182. Miranda A, Jarque S, Rosel J. Treatment of children with ADHD: Psychopedagogical program at school versus psychoestimulant medication. Psicothema. 2006;18(3):335-41.

183. Ohan JL, Cormier N, Hepp SL, Visser TAW, Strain MC. Does knowledge about attentiondefi cit/hyperactivity disorder impact teachers’ reported behaviors and perceptions? Sch Psychol Q. 2008 Sep;23(3):436-49.

184. Purdie N, Hattie J, Carroll A. A review of the research on interventions for attention defi cit hyperactivity disorder: What works best? Review of Educational Research. 2002 Mar;72(1):61-99.

185. Tymms P, Merrell C. The impact of screening and advice on inattentive, hyperactive and impulsive children. European Journal of Special Needs Education. 2006 Aug;21(3):321-37.

186. Fowler M, National Education Committee. CH.A.D.D. Educator’s Manual: an In-Depth Look at Attention Defi cit Disorders from an Educational Perspective. Plantation, Florida: CH.A.D.D.; 1992.

187. Corkum PV, McKinnon MM, Mullane JC. The effect of involving classroom teachers in a parent training program for families of children with ADHD. Child Fam Behav Ther. 2005;27(4):29-49.

188. Braswell L, August GJ, Bloomquist ML, Realmuto GM, Skare SS, Crosby RD. School-based secondary prevention for children with disruptive behavior: initial outcomes. J Abnorm Child Psychol. 1997 Jun;25(3):197-208.

189. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder -- fi rst upgrade. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30.

190. Bezchlibnyk-Butler KZ, Virani AS, Carrey NJ, Martin BA. Clinical Handbook of Psychotropic Drugs for children and adolescent. 2a. ed. Ontario: Hogrefe y Huber Publishers; 2007.

191. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry. 2004 Jul;161(7):1173-80.

192. Bezchlibnyk-Butler K, Virani A. Drugs for attention defi cit hyperactivity disorder. En: Bezchlibnyk- Butler K, Virani A, editors. Clinical handbook of psychotropic drugs for children and adolescent. Ontario: Hogrefe & Huber Publishers; 2004. pp. 11-25.

193. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006 Dec;15(8):476-95.

194. Mardomingo MJ. Estimulantes de liberación prolongada. Comentario a la Guía Europea de tratamiento del TDAH. Evidencias Científi cas 2007.

195. Wolraich ML, McGuinn L, Doffi ng M. Treatment of attention defi cit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf. 2007;30(1):17-26.

196. Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, et al. Treatment of attention-defi cit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005 Jun;115(6): e749-e757.

197. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH, Jr. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002 Mar;41(3):253-61.

198. Cheng JYW, Chen RYL, Ko JSN, Ng EML. Effi cacy and safety of atomoxetine for attention defi cit/hyperactivity disorder in children and adolescents--Meta-analysis and meta-regression analysis. Psychopharmacology. 2007 Oct;194(2):197-209.

199. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the effi cacy of medications for ADHD using meta-analysis. MedGenMed. 2006;8(4):4.

200. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention defi cit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13. Systematic review. 2006.

201. King S, Griffi n S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention defi cit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006 Jul;10(23):iii-146.

202. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention defi cit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008 Jun;165(6):721-30.

203. Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention defi cit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007 Mar;41(3):222-30.

204. Butter HJ, Lapierre Y, Firestone P, Blank A. A comparative study of the effi cacy of ACTH4-9 analog, methylphenidate, and placebo on attention defi cit disorder with hyperkinesis. J Clin Psychopharmacol. 1983 Aug;3(4):226-30.

205. Conners CK, Taylor E. Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Arch Gen Psychiatry. 1980 Aug;37(8):922-30.

206. Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder. Eur Child Adolesc Psychiatry. 2006 Dec;15(8): 450-9.

207. Gittelman-Klein R, Klein DF, Katz S, Saraf K, Pollack E. Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results. Arch Gen Psychiatry. 1976 Oct;33(10):1217-31.

208. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-defi cit/hyperactivity disorder. Pediatrics. 2002 Mar;109(3):E39.

209. Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H. Effi cacy and safety of dexmethylphenidate extended-release capsules in children with attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):817-23.

210. Ialongo NS, Lopez M, Horn WF, Pascoe JM. Effects of psychostimulant medication on selfperceptions of competence, control, and mood in children with attention deficit hyperactivity disorder. J Clin Child Psychol. 1994 Jun;23(2):161-73.

211. Kollins S, Greenhill L, Swanson J, Wigal S, Abikoff H, McCracken J, et al. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1275-83.

212. Kurlan R, Goetz CG, McDermott MP. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58:527-36.

213. Lerer RJ, Lerer MP, Artner J. The effects of methylphenidate on the handwriting of children with minimal brain dysfunction. J Pediatr. 1977 Jul;91(1):127-32.

214. Pliszka SR, Browne RG, Olvera RL, Wynne SK. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000 May;39(5):619-26.

215. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attentiondeficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90.

216. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Placebo-controlled evaluation of Ritalin side effects. Pediatrics. 1993 Jun;91(6):1101-6.

217. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention defi cit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990 Aug;86(2):184-92.

218. Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol. 2004;14(2):185-94.

219. Poncin Y, Sukhodolsky DG, McGuire J, Scahill L. Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry. 2007 Jun;16 Suppl 1:78-88.

220. Aman MG, Kern RA, Osborne P, Tumuluru R, Rojahn J, del Médico V. Fenfl uramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects. Am J Ment Retard. 1997 Mar;101(5):521-34.

221. Amery B, Minichiello MD, Brown GL. Aggression in hyperactive boys: response to d-amphetamine. J Am Acad Child Psychiatry. 1984 May;23(3):291-4.

222. Gadow KD, Nolan EE, Sverd J, Sprafkin J, Paolicelli L. Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry. 1990 Sep;29(5):710-8.

223. Hinshaw SP, Henker B, Whalen CK. Self-control in hyperactive boys in anger-inducing situations: effects of cognitive-behavioral training and of methylphenidate. J Abnorm Child Psychol. 1984 Mar;12(1):55-77.

224. Hinshaw SP, Buhrmester D, Heller T. Anger control in response to verbal provocation: effects of stimulant medication for boys with ADHD. J Abnorm Child Psychol. 1989 Aug;17(4):393-407.

225. Hinshaw SP, Henker B, Whalen CK, Erhardt D, Dunnington RE, Jr. Aggressive, prosocial, and nonsocial behavior in hyperactive boys: dose effects of methylphenidate in naturalistic settings. J Consult Clin Psychol. 1989 Oct;57(5):636-43.

226. Hinshaw SP, Heller T, McHale JP. Covert antisocial behavior in boys with attention-defi cit hyperactivity disorder: external validation and effects of methylphenidate. J Consult Clin Psychol. 1992 Apr;60(2):274-81.

227. Kaplan SL, Busner J, Kupietz S, Wassermann E, Segal B. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report. J Am Acad Child Adolesc Psychiatry. 1990 Sep;29(5):719-23.

228. Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modifi cation in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):578-86.

229. Murphy DA, Pelham WE, Lang AR. Aggression in boys with attention defi cit-hyperactivity disorder: methylphenidate effects on naturalistically observed aggression, response to provocation, and social information processing. J Abnorm Child Psychol. 1992 Oct;20(5):451-66.

230. Pelham WE, Bender ME, Caddell J, Booth S, Moorer SH. Methylphenidate and children with attention defi cit disorder. Dose effects on classroom academic and social behavior. Arch Gen Psychiatry. 1985 Oct;42(10):948-52.

231. Pelham WE, Jr., Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Milich R, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention defi cit disorder. Pediatrics. 1987 Oct;80(4):491-501.

232. Pelham WE, Jr., Walker JL, Sturges J, Hoza J. Comparative effects of methylphenidate on ADD girls and ADD boys. J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):773-6.

233. Pelham WE, Jr., Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, et al. Relative effi cacy of long-acting stimulants on children with attention defi cit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained- release dextroamphetamine, and pemoline. Pediatrics. 1990 Aug;86(2):226-37.

234. Pelham WE, Milich R, Cummings EM, Murphy DA, Schaughency EA, Greiner AR. Effects of background anger, provocation, and methylphenidate on emotional arousal and aggressive responding in attention-defi cit hyperactivity disordered boys with and without concurrent aggressiveness. J Abnorm Child Psychol. 1991 Aug;19(4):407-26.

235. Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, et al. A comparison of ritalin and adderall: effi cacy and time-course in children with attention-defi cit/hyperactivity disorder. Pediatrics. 1999 Apr;103(4):e43.

236. Smith BH, Pelham WE, Evans S, Gnagy E, Molina B, Bukstein O, et al. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol. 1998 May;6(2):187-204.

237. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry. 1991 Mar;30(2):246-56.

238. Arnold LE, Wender PH, McCloskey K, Snyder SH. Levoamphetamine and dextroamphetamine: comparative effi cacy in the hyperkinetic syndrome. Assessment by target symptoms. Arch Gen Psychiatry. 1972;27:816-22.

239. Arnold LE, Huestis RD, Smeltzer DJ, Scheib J, Wemmer D, Colner G. Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arch Gen Psychiatry. 1976 Mar;33(3): 292-301.

240. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. The response of aggressive and nonaggressive ADHD children to two doses of methylphenidate. J Am Acad Child Adolesc Psychiatry. 1989 Nov;28(6):873-81.

241. Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, et al. Bupropion versus methylphenidate in the treatment of attention-defi cit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 May;34(5):649-57.

242. Bostic JQ, Biederman J, Spencer TJ, Wilens TE, Prince JB, Monuteaux MC, et al. Pemoline treatment of adolescents with attention defi cit hyperactivity disorder: a short-term controlled trial. J Child Adolesc Psychopharmacol. 2000;10(3):205-16.

243. Bukstein OG, Kolko DJ. Effects of methylphenidate on aggressive urban children with attention defi cit hyperactivity disorder. J Clin Child Psychol. 1998 Oct;27(3):340-51.

244. Klorman R, Brumaghim JT, Salzman LF, Strauss J, Borgstedt AD, McBride MC, et al. Effects of methylphenidate on attention-defi cit hyperactivity disorder with and without aggressive/ noncompliant features. J Abnorm Psychol. 1988 Nov;97(4):413-22.

245. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med. 1987 Feb;17(1):121-43.

246. Pelham WE Jr, Swanson JM, Furman MB, Schwindt H. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry. 1995;34:1504-13.

247. Fitzpatrick PA, Klorman R, Brumaghim JT, Borgstedt AD. Effects of sustained-release and standard preparations of methylphenidate on attention defi cit disorder. J Am Acad Child Adolesc Psychiatry. 1992 Mar;31(2):226-34.

248. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-defi cit/hyperactivity disorder. Pediatrics. 2001 Oct;108(4):883-92.

249. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001 Jun;107(6):E105.

250. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention defi cit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30-5.

251. Bohnstedt BN, Kronenberger WG, Dunn DW, Giauque AL, Wood EA, Rembusch ME, et al. Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants. J Atten Disord. 2005 May;8(4):153-9.

252. Brown RT, Perwien A, Faries DE, Kratochvil CJ, Vaughan BS. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila) 2006 Nov;45(9):819-27.

253. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, et al. Once-daily atomoxetine treatment for children with attention-defi cit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004 Jul;114(1):e1-e8.

254. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-defi cit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001 Nov;108(5):E83.

255. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention defi cit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 Nov;159(11):1896-901.

256. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double- blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7): 896-904.

257. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention- defi cit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7.

258. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005 Jul;44(7):647-55.

259. Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(1941):1949.

260. Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. A randomized, double-blind study of continuation treatment for attention-defi cit/hyperactivity disorder after 1 year. Biol Psychiatry. 2006;61(5):694-9.

261. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, et al. Effi cacy and safety of atomoxetine in childhood attention-defi cit/hyperactivity disorder with comorbid oppositional defi ant disorder. J Atten Disord. 2004 Oct;8(2):45-52.

262. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-defi cit/hyperactivity disorder and comorbid oppositional defi ant disorder. J Am Acad Child Adolesc Psychiatry. 2005 Mar;44(3):240-8.

263. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003 Aug;42(8):886-94.

264. Palumbo DR, Sallee FR, Pelham WE, Jr., Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-defi cit/hyperactivity disorder: I. Effi cacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):180-8.

265. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Jr., et al. Clonidine for attention-defi cit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):189-98.

266. Casat CD, Pleasants DZ, Van Wyck FJ. A double-blind trial of bupropion in children with attention defi cit disorder. Psychopharmacol Bull.1987;23(1):120-2.

267. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, et al. Bupropion hydrochloride in attention defi cit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10):1314-21.

268. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, et al. Effi cacy and safety of modafi nil fi lm-coated tablets in children and adolescents with attention-defi cit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fl exible-dose study. Pediatrics. 2005 Dec;116(6):e777-e784.

269. Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA. A comparison of once-daily and divided doses of modafi nil in children with attention-defi cit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry. 2006 May;67(5):727-35.

270. Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, et al. A randomized, double-blind, placebo-controlled study of modafinil fi lm-coated tablets in children and adolescents with attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):503-11.

271. Rugino TA, Samsock TC. Modafi nil in children with attention-defi cit hyperactivity disorder. Pediatr Neurol. 2003 Aug;29(2):136-42.

272. Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, et al. Modafi nil fi lm-coated tablets in children and adolescents with attention-defi cit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fi xed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006 Jan;67(1):137-47.

273. Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffi n S. Pharmacotherapy of attention-defi cit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409-32.

274. Green WH. Nonstimulant drugs in the treatment of attention defi cit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 1992;1:449-65.

275. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Effi cacy. J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):777-84.

276. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-defi cit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999 Nov;(11):i-341.

277. Rapport MD, Carlson GA, Kelly KL, Pataki C. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry. 1993 Mar;32(2):333-42.

278. Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S. A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry. 1993 Jan;32(1):199-204.

279. Donnelly M, Zametkin AJ, Rapoport JL, Ismond DR, Weingartner H, Lane E, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther. 1986 Jan;39(1):72-81.

280. Gualtieri CT, Keenan PA, Chandler M. Clinical and neuropsychological effects of desipramine in children with attention defi cit hyperactivity disorder. J Clin Psychopharmacol. 1991 Jun;11(3):155-9.

281. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-defi cit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995 Jan;95(1):74-81.

282. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, et al. Six-week, double- blind, placebo-controlled study of desipramine for adult attention defi cit hyperactivity disorder. Am J Psychiatry. 1996 Sep;153(9):1147-53.

283. Gualtieri CT, Evans RW. Motor performance in hyperactive children treated with imipramine. Percept Mot Skills. 1988 Jun;66(3):763-9.

284. Winsberg BG, Kupietz SS, Yepes LE, Goldstein S. Ineffectiveness of imipramine in children who fail to respond to methylphenidate. J Autism Dev Disord. 1980 Jun;10(2):129-37.

285. Werry JS, Aman MG, Diamond E. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry. 1980 Jan;21(1):27-35.

286. Arabgol F, Panaghi L, Hebrani P. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry. 2009 Jan;18(1):53-9.

287. Donnelly M, Haby MM, Carter R, Andrews G, Vos T. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention defi cit hyperactivity disorder. Aust N Z J Psychiatry. 2004 Aug;38(8):592-601.

288. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf. 2001 Mar;10(2):85-94.

289. Narayan S, Hay J. Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the fi rst-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res. 2004;4(6):625-34.

290. Zupancic JAF, Miller A, Raina P. Economic evaluation of pharmaceutical and psychological/ behavioural therapies for attentiondefi cit/hyperactivity disorder. En: Miller A, Lee SK, Raina P, et al., editors. A Review of Therapies for Attention Defi cit/Hyperactivity Disorder.Ottawa: Canadian Coordinating Offi ce for Health Technology Assessment. 1998; pp. 132-62.

291. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year followup of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):989-1002.

292. Kupietz SS, Winsberg BG, Richardson E. Effects of methylphenidate dosage in hyperactive reading-disabled children: I. Behavior and cognitive performance effects. J Am Acad Child Adolesc Psychiatry. 1988;27:70-7.

293. Quinn PO, Rapoport JL. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry. 1975 Mar;132(3):241-5.

294. Conrad WG, Dworkin ES, Shai A, Tobiessen JE. Effects of amphetamine therapy and prescriptive tutoring on the behavior and achievement of lower class hyperactive children. J Learn Disabil. 1971;4:509-17.

295. Firestone P, Crowe D, Goodman JT, McGrath P. Vicissitudes of follow-up studies: Differential effects of parent training and stimulant medication with hyperactives. Am J Orthopsychiatry. 1986 Apr;56(2):184-94.

296. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, et al. Longterm stimulant treatment of children with attention-defi cit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997 Sep;54(9): 857-64.

297. Gittelman-Klein R, Klein DF, Abikoff H, Katz S, Gloisten AC, Kates W. Relative effi cacy of methylphenidate and behavior modifi cation in hyperkinetic children: an interim report. J Abnorm Child Psychol. 1976;4(4):361-79.

298. Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):754-63.

299. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, et al. Effects of long-term atomoxetine treatment for young children with attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-27.

300. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, et al. Long-term atomoxetine treatment in adolescents with attention-defi cit/hyperactivity disorder. J Pediatr. 2006 Jul;149(1):112-9.

301. FDA Alert [09/05]: Suicidal thinking in children and adolescents. U S Food and Drug Administration 2005 December 29. Disponible en: URL: http://www.fda.gov/cder/drug/infopage/ atomoxetine/default.htm.

302. Charach A, Ickowicz A, Schachar R. Stimulant treatment over fi ve years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004 May;43(5):559-67.

303. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-defi cit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006 Feb;27(1):1-10.

304. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientifi c statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008 May 6;117(18):2407-23.

305. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40.

306. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-defi cit/hyperactivity disorder. Pediatrics. 2008 Aug;122(2):451-3.

307. Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, et al. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-defi cit/hyperactivity disorder--a preliminary tolerability and effi cacy study. Clin Ther. 2007 Jun;29(6):1168-77.

308. Weiss MD, Virani A, Wasdell M, Faulkner L, Rea K. Atomoxetine in clinical practice. Future Neurology. 2006;1:249-58.

309. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-defi cit/hyperactivity disorder. Pediatrics. 2003 Nov;112(5):e404.

310. Wilens TE, Kratochvil C, Newcorn JH, Gao H. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry. 2006 Feb;45(2): 149-57.

311. Cox DJ, Humphrey JW, Merkel RL, Penberthy JK, Kovatchev B. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-defi cit/ hyperactivity disorder. J Am Board Fam Pract. 2004 Jul;17(4):235-9.

312. Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006 Apr;45(4):415-21.

313. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004 Apr;113(4):762-9.

314. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1015-27.

315. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-defi cit/ hyperactivity disorder. Pediatrics. 2005 Jul;116(1):e74-e80.

316. Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, et al. Effects of atomoxetine on growth in children with attention-defi cit/hyperactivity disorder following up to fi ve years of treatment. J Child Adolesc Psychopharmacol. 2007 Oct;17(5):689-700.

317. Wilens TE, Monuteaux MC, Snyder LE, Moore H, Whitley J, Gignac M. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-defi cit/hyperactivity disorder: what does the literature tell us? J Child Adolesc Psychopharmacol. 2005 Oct;15(5):787-98.

318. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attentiondefi cit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003 Jan;111(1):179-85.

319. Wilens TE, Adamson J, Monuteaux MC, Faraone SV, Schillinger M, Westerberg D, et al. Effect of prior stimulant treatment for attention-defi cit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008 Oct;162(10):916-21.

320. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008 May;165(5):597-603.

321. Abikoff H, Hechtman L, Klein RG, Weiss G, Fleiss K, Etcovitch J, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7):802-11.

322. Firestone P, Kelly MJ, Goodman JT, Davey J. Differential effects of parent training and stimulant medication with hyperactives: A progress report. J Am Acad Child Psychiatry. 1981;20(1): 135-47.

323. Lord J, Paisley S. The Clinical Effectiveness and Cost-Effectiveness of Methylphenidate for Hyperactivity in Childhood, Version 2. London: NICE; 2000.

324. Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, et al. Cost-effectiveness of ADHD treatments: fi ndings from the multimodal treatment study of children with ADHD. Am J Psychiatry. 2005 Sep;162(9):1628-36.

325. Foster EM, Jensen PS, Schlander M, Pelham WE, Jr., Hechtman L, Arnold LE, et al. Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res. 2007 Feb;42(1 Pt 1):165-82.

326. Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-defi cit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008 Feb;12(2):217-33.

327. Schubert R. Attention defi cit disorder and epilepsy. Pediatr Neurol. 2005 Jan;32(1):1-10.

328. Artigas-Pallarés J. Comorbilidad en el trastorno por défi cit de atención/hiperactividad. Rev Neurol. 2003;36(Supl 1):S68-78.

329. Fuentes-Biggi J, Ferrari-Arroyo MJ, Boada-Muñoz L, Tourino-Aguilera E, Artigas-Pallarés J, Belinchon-Carmona M, et al. Good practice guidelines for the treatment of autistic spectrum disorders. Rev Neurol. 2006 Oct 1;43(7):425-38.

330. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-defi cit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006 Oct;16(5): 599-610.

331. Troost PW, Steenhuis MP, Tuynman-Qua HG, Kalverdijk LJ, Buitelaar JK, Minderaa RB, et al. Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: A Pilot Study. J Child Adolesc Psychopharmacology. 2006 Oct;16(5):611-9.

332. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention- defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 Jun;45(6):642-57.

333. Sumner CS, Donnelly C, Lopez FA, Sutton V, Bakken R, Paczkowski M, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. Presented at: Annual Meeting of the American Psychiatric Association. 2005.

334. Bangs ME, Emslie GJ, Spencer T, Ramsey Jl, Detke HC, Allen AJ, et al. A study of atomoxetine in adolescents with ADHD and comorbid depression. 2005.

335. McClellan J, Kowatch RA, Findling RL. Practice Parameter for the Assessmentand Treatment of Children and Adolescents With Bipolar Disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107-125.

336. Consoli A, Bouzamondo A, Guile JM, Lechat P, Cohen D. Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis. Can J Psychiatry. 2007 May;52(5):323-8.

337. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005 Mar;44(3):213-35.

338. State RC, Frye MA, Altshuler LL. Chart review of the impact of attention-defi cit/hyperactivity disorder comorbidity on respondse to lithium of divalproex sodium in adolescent mania. J Clin Psychiatry. 2004;65:1057-63.

339. Biederman J, Mick E, Prince J, Bostic JQ, Wilens TE, Spencer T, et al. Systematic chart review of the pharmacologic treatment of comorbid attention defi cit hyperactivity disorder in youth with bipolar disorder. J Child Adolesc Psychopharmacology. 1999 Dec;9(4):247-56.

340. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord. 2008 Sep;12(2):115-25.

341. Upadhyaya HP. Managing attention-defi cit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry. 2007;68 Suppl 11:23-30.

342. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21-31.

343. Chan E. The role of complementary and alternative medicine in attention-defi cit hyperactivity disorder. J Dev Behav Pediatr. 2002 Feb;23(1 Suppl):S37-S45.

344. Complementary and Alternative Medicine. NIH 2009 February 5. Disponible en: URL: http: //www.nlm.nih.gov/medlineplus/spanish/complementaryandalternativemedicine.html.

345. Coulter MK, Dean ME. Homeopathy for attention defi cit/hyperactivity disorder or hyperkinetic disorder. Cochrane Database Syst Rev 2007;(4):CD005648.

346. Weber W, Vander Stoep A, McCarty RL. Hypericum perforatum (St. John’s Wort) for Attention- Defi cit/Hyperactivity Disorder in Children and Adolescents. JAMA. 2008;229:2633-41.

347. Pintov S, Hochman M, Livne A, Heyman E, Lahat E. Bach fl ower remedies used for attention defi cit hyperactivity disorder in children--a prospective double blind controlled study. Eur J Paediatr Neurol. 2005;9:395-8.

348. Jacobs J, Williams AL, Girard C, Njike VY, Katz D. Homeopathy for attention-defi cit/hyperactivity disorder: a pilot randomized-controlled trial. J Altern Complement Med. 2005 Oct;11(5):799-806.

349. Lamont J. Homeopathic treatment of attention defi cit hyperactivity disorder: a controlled trial. Br Homeopath J. 1997;86:196-200.

350. Strauss LC. The effi cacy of a homeopathic preparation in the management of attention defi cit hyperactivity disorder. Biomedical Therapy. 2000;18(2):197-201.

351. Frei H, Everts R, von Ammon K, Kaufmann F, Walther D, Hsu-Schmitz SF, et al. Homeopathic treatment of children with attention defi cit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. Eur J Pediatr. 2005 Dec;164(12):758-67.

352. Loo SK. The EEG and ADHD. ADHD Rep. 2003;11:1-14.

353. Nuñez G, Fernández Vidal J. Juego y psicomotricidad. Madrid: Cepe ed. 1994.

354. Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):378-85.

355. Quintero Gutiérrez del Álamo FJ, Sansebastián J, García Álvarez R, Correas J, Barbudo E, Puente R, et al. Características clínicas del trastorno por défi cit de atención e hiperactividad (TDAH) en la infancia. En: Quintero Gutiérrez del Álamo FJ, Correas J, Quintero Lumbreras FJ, editores. Trastorno por Déficit de Atención e Hiperactividad a lo largo de la vida. Madrid: Ergón; 2006. pp. 75-88.

356. Código Civil Español. Art. 211. 2009.

357. Ley 41/2002, de 14 de Noviembre, básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica. BOE núm. 274. 2002.

358. Código Civil Español. Arts. 154-163. 2009.

359. Canadian Attention Deficit Hyperactivity Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 2007.

360. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. Evidence-based guidelines for management of attention-defi cit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007 Jan;21(1):10-41.

361. University of Michigan Health System. Guidelines for Clinical Care: Attention Deficit Hyperactivity Disorder. 2005.


Última actualización: septiembre 2011

Logo del Ministerio de Ciencia e InnovaciónLogo del Ministerio de Sanidad y Consumo Logo del Plan de Calidad del Sistema Nacional de SaludAgència d’Avaluació de Tecnologia i Recerca Mèdiques de Cataluña

 

Copyright | Ayuda | Mapa